CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $510,000 | -27.6% | 3,334 | -60.4% | 0.00% | -33.3% |
| Q3 2020 | $704,000 | +13.7% | 8,423 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $619,000 | +79.9% | 8,423 | +3.9% | 0.00% | +50.0% |
| Q1 2020 | $344,000 | -30.4% | 8,109 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $494,000 | +48.8% | 8,109 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $332,000 | -14.2% | 8,109 | -1.2% | 0.00% | 0.0% |
| Q2 2019 | $387,000 | +31.6% | 8,209 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $294,000 | +12.6% | 8,209 | +84.9% | 0.00% | +100.0% |
| Q2 2018 | $261,000 | +29.2% | 4,440 | +0.2% | 0.00% | 0.0% |
| Q1 2018 | $202,000 | – | 4,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |